Drug Profile
Esmirtazapine
Alternative Names: Esmirtazapine maleate; ORG-50081; SCH 900265Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Organon
- Developer Merck & Co
- Class Dibenzazepines; Sleep disorder therapies; Small molecules
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia; Vasomotor symptoms
Most Recent Events
- 01 Mar 2010 Discontinued - Phase-III for Insomnia in Canada (PO)
- 01 Mar 2010 Discontinued - Phase-III for Insomnia in USA (PO)
- 01 Mar 2010 Discontinued - Phase-III for Vasomotor symptoms in Australia (PO)